Valuation: Myriad Genetics, Inc.

Market Cap 306M 262M 245M 225M 421M 29.29B 427M 2.9B 1.13B 14.71B 1.15B 1.12B 48.66B P/E 2026 *
-2.01x
P/E 2027 * -2.62x
Enterprise Value 306M 262M 245M 225M 421M 29.29B 427M 2.9B 1.13B 14.71B 1.15B 1.12B 48.66B EV / Sales 2026 *
0.39x
EV / Sales 2027 * 0.37x
Free-Float
96.03%
Yield 2026 *
-
Yield 2027 * -
1 day-0.62%
1 week+5.61%
Current month+11.89%
1 month-45.85%
3 months-18.16%
6 months-25.41%
Current year-47.97%
1 week 2.84
Extreme 2.835
3.3
1 month 2.74
Extreme 2.74
5.82
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
36.95
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap.
8/16/26 Tax

Chief Financial Officer

-8,761 0.0093%
6/11/26 Free

Chief Executive Officer

3,542 0.0038%
3/22/26 Tax

Chief Operating Officer

2,055 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%+5.61%-45.11%-81.96% 308M
+1.67%+8.57%+178.54%+352.16% 22.53B
-0.13%+1.92%-41.52%-19.91% 10.25B
+1.96%+16.10%+397.10%+40.59% 8.32B
+6.88%+20.50%-31.09% - 6.95B
-0.27%-0.97%+68.98%+48.50% 6.54B
-4.95%+1.23%-12.97%-3.17% 6.37B
+1.49%-3.43%+69.95%+106.00% 4.34B
+0.56%+0.97%-12.93%-15.99% 4.32B
-0.86%+2.76%-17.52%-26.19% 2.97B
Average +0.57%+4.08%+55.34%+44.45% 7.29B
Weighted average by Cap. +1.00%+5.80%+99.25%+131.19%

Financials

2026 *2027 *
Net sales 778M 666M 623M 571M 1.07B 74.41B 1.08B 7.36B 2.87B 37.38B 2.92B 2.86B 124B 822M 704M 659M 603M 1.13B 78.63B 1.15B 7.78B 3.03B 39.5B 3.09B 3.02B 131B
Net income -143M -123M -115M -105M -197M -13.71B -200M -1.36B -529M -6.89B -538M -526M -22.79B -104M -88.92M -83.2M -76.16M -143M -9.93B -145M -983M -383M -4.99B -390M -381M -16.5B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-08-21 US$3.200 -0.62% 1,279,033
26-08-20 US$3.220 +0.94% 1,928,362
26-08-19 US$3.190 +11.15% 2,194,148
26-08-18 US$2.870 -5.90% 2,041,073
26-08-17 US$3.050 +0.66% 1,387,825
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
3.200USD
Average target price
3.769USD
Spread / Average Target
+17.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock